COVID-19 Therapeutics: Making Sense of It All
- 15 September 2020
- journal article
- research article
- Published by AACN Publishing in AACN Advanced Critical Care
- Vol. 31 (3), 239-249
- https://doi.org/10.4037/aacnacc2020792
Abstract
No abstract availableThis publication has 33 references indexed in Scilit:
- A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19The New England Journal of Medicine, 2020
- Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) — United States, February 12–March 16, 2020Morbidity and Mortality Weekly Report (MMWR), 2020
- Faculty Opinions recommendation of A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.Published by H1 Connect ,2020
- Prominent changes in blood coagulation of patients with SARS-CoV-2 infectioncclm, 2020
- Early, low-dose and short-term application of corticosteroid treatment in patients with severe COVID-19 pneumonia: single-center experience from Wuhan, ChinaPublished by Cold Spring Harbor Laboratory ,2020
- In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)Clinical Infectious Diseases, 2020
- Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumoniaJournal of Thrombosis and Haemostasis, 2020
- Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymeraseAntiviral Research, 2019
- Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronavirusesScience Translational Medicine, 2017
- Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeysNature, 2016